{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:28:08Z","timestamp":1775100488943,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/gt.2017.2","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T15:41:17Z","timestamp":1484149277000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer"],"prefix":"10.1038","volume":"24","author":[{"given":"W","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J B","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"BFgt20172_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"BFgt20172_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A . Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"BFgt20172_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ejso.2013.10.010","volume":"39","author":"F Roviello","year":"2013","unstructured":"Roviello F, Caruso S, Neri A, Marrelli D . Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol 2013; 39: 1309\u20131316.","journal-title":"Eur J Surg Oncol"},{"key":"BFgt20172_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00595-013-0603-8","volume":"44","author":"M Imano","year":"2014","unstructured":"Imano M, Okuno K . Treatment strategies for gastric cancer patients with peritoneal metastasis. Surg Today 2014; 44: 399\u2013404.","journal-title":"Surg Today"},{"key":"BFgt20172_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/bjs.1800830605","volume":"83","author":"AM Averbach","year":"1996","unstructured":"Averbach AM, Jacquet P . Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726\u2013733.","journal-title":"Br J Surg"},{"key":"BFgt20172_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0960-7404(92)90034-I","volume":"1","author":"S Moriguchi","year":"1992","unstructured":"Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y . Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992; 1: 341\u2013346.","journal-title":"Surg Oncol"},{"key":"BFgt20172_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18: 1575\u20131581.","journal-title":"Ann Surg Oncol"},{"key":"BFgt20172_CR8","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116: 5608\u20135618.","journal-title":"Cancer"},{"key":"BFgt20172_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.mt.6300321","volume":"16","author":"F Kreppel","year":"2008","unstructured":"Kreppel F, Kochanek S . Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16\u201329.","journal-title":"Mol Ther"},{"key":"BFgt20172_CR10","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.3390\/v7112923","volume":"7","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL . Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 2015; 7: 6009\u20136042.","journal-title":"Viruses"},{"key":"BFgt20172_CR11","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-10-0205","volume":"9","author":"R Sakai","year":"2010","unstructured":"Sakai R, Kagawa S, Yamasaki Y, Kojima T, Uno F, Hashimoto Y et al. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. Mol Cancer Ther 2010; 9: 1884\u20131893.","journal-title":"Mol Cancer Ther"},{"key":"BFgt20172_CR12","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 2015; 6: 19976\u201319989.","journal-title":"Oncotarget"},{"key":"BFgt20172_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1172\/JCI9180","volume":"106","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763\u2013771.","journal-title":"J Clin Invest"},{"key":"BFgt20172_CR14","first-page":"3438","volume":"62","author":"K Tsukuda","year":"2002","unstructured":"Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM . An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002; 62: 3438\u20133447.","journal-title":"Cancer Res"},{"key":"BFgt20172_CR15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/gt.2010.34","volume":"17","author":"SH Ma","year":"2010","unstructured":"Ma SH, Chen GG, Yip J, Lai PB . Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice. Gene Therapy 2010; 17: 905\u2013912.","journal-title":"Gene Therapy"},{"key":"BFgt20172_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.canlet.2012.01.009","volume":"319","author":"C Xu","year":"2012","unstructured":"Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L et al. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett 2012; 319: 154\u2013163.","journal-title":"Cancer Lett"},{"key":"BFgt20172_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1126\/science.7605428","volume":"266","author":"NW Kim","year":"1994","unstructured":"Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011\u20132015.","journal-title":"Science"},{"key":"BFgt20172_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/sj.cgt.7700944","volume":"13","author":"JJ Davis","year":"2006","unstructured":"Davis JJ, Wang L, Dong F, Zhang L, Guo W, Teraishi F et al. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther 2006; 13: 720\u2013723.","journal-title":"Cancer Gene Ther"},{"key":"BFgt20172_CR19","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A . Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687\u201312690.","journal-title":"J Biol Chem"},{"key":"BFgt20172_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673\u2013682.","journal-title":"Immunity"},{"key":"BFgt20172_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone RW, Frew AJ, Smyth MJ . The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782\u2013798.","journal-title":"Nat Rev Cancer"},{"key":"BFgt20172_CR22","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1038\/sj.onc.1205926","volume":"21","author":"T Lin","year":"2002","unstructured":"Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020\u20138028.","journal-title":"Oncogene"},{"key":"BFgt20172_CR23","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1158\/1078-0432.CCR-06-0244","volume":"12","author":"F Dong","year":"2006","unstructured":"Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W et al. Eliminating established tumor in nu\/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006; 12: 5224\u20135230.","journal-title":"Clin Cancer Res"},{"key":"BFgt20172_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cgt.2010.83","volume":"18","author":"W Zhou","year":"2011","unstructured":"Zhou W, Zhu H, Chen W, Hu X, Pang X, Zhang J et al. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer Gene Ther 2011; 18: 336\u2013345.","journal-title":"Cancer Gene Ther"},{"key":"BFgt20172_CR25","first-page":"3620","volume":"62","author":"T Lin","year":"2002","unstructured":"Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA et al. Targeted expression of green fluorescent protein\/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620\u20133625.","journal-title":"Cancer Res"},{"key":"BFgt20172_CR26","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1158\/1078-0432.CCR-03-0512","volume":"10","author":"D Jacob","year":"2004","unstructured":"Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S et al. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 2004; 10: 3535\u20133541.","journal-title":"Clin Cancer Res"},{"key":"BFgt20172_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cgt.2009.44","volume":"17","author":"M Takakura","year":"2010","unstructured":"Takakura M, Nakamura M, Kyo S, Hashimoto M, Mori N, Ikoma T et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010; 17: 11\u201319.","journal-title":"Cancer Gene Ther"},{"key":"BFgt20172_CR28","first-page":"33","volume":"9","author":"S Wadler","year":"2003","unstructured":"Wadler S, Yu B, Tan JY, Kaleya R, Rozenblit A, Makower D et al. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin Cancer Res 2003; 9: 33\u201343.","journal-title":"Clin Cancer Res"},{"key":"BFgt20172_CR29","doi-asserted-by":"publisher","first-page":"33099","DOI":"10.1074\/jbc.273.50.33099","volume":"273","author":"M Nguyen","year":"1998","unstructured":"Nguyen M, Branton PE, Roy S, Nicholson DW, Alnemri ES, Yeh WC et al. E1A-induced processing of procaspase-8 can occur independently of FADD and is inhibited by Bcl-2. J Biol Chem 1998; 273: 33099\u201333102.","journal-title":"J Biol Chem"},{"key":"BFgt20172_CR30","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1128\/jvi.71.5.3526-3533.1997","volume":"71","author":"E Querido","year":"1997","unstructured":"Querido E, Teodoro JG, Branton PE . Accumulation of p53 induced by the adenovirus E1A protein requires regions involved in the stimulation of DNA synthesis. J Virol 1997; 71: 3526\u20133533.","journal-title":"J Virol"},{"key":"BFgt20172_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/1535-7163.MCT-15-0644","volume":"15","author":"M Ishida","year":"2016","unstructured":"Ishida M, Kagawa S, Shimoyama K, Takehara K, Noma K, Tanabe S et al. Trastuzumab-based photoimmunotherapy integrated with viral HER2 transduction inhibits peritoneally disseminated HER2-negative cancer. Mol Cancer Ther 2016; 15: 402\u2013411.","journal-title":"Mol Cancer Ther"},{"key":"BFgt20172_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/bjc.2015.229","volume":"113","author":"R Natatsuka","year":"2015","unstructured":"Natatsuka R, Takahashi T, Serada S, Fujimoto M, Ookawara T, Nishida T et al. Gene therapy with SOCS1 for gastric cancer induces G2\/M arrest and has an antitumour effect on peritoneal carcinomatosis. Br J Cancer 2015; 113: 433\u2013442.","journal-title":"Br J Cancer"},{"key":"BFgt20172_CR33","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-06-0024","volume":"12","author":"T Tanaka","year":"2006","unstructured":"Tanaka T, Huang J, Hirai S, Kuroki M, Watanabe N, Tomihara K et al. Carcinoembryonic antigen-targeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors. Clin Cancer Res 2006; 12: 3803\u20133813.","journal-title":"Clin Cancer Res"},{"key":"BFgt20172_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/gut.2003.021683","volume":"53","author":"Y Tsunemitsu","year":"2004","unstructured":"Tsunemitsu Y, Kagawa S, Tokunaga N, Otani S, Umeoka T, Roth JA et al. Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer. Gut 2004; 53: 554\u2013560.","journal-title":"Gut"},{"key":"BFgt20172_CR35","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1074\/jbc.273.9.4972","volume":"273","author":"B Fang","year":"1998","unstructured":"Fang B, Ji L, Bouvet M, Roth JA . Evaluation of GAL4\/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 1998; 273: 4972\u20134975.","journal-title":"J Biol Chem"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt20172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt20172","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt20172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:21:48Z","timestamp":1648560108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt20172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFgt20172"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.2","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"assertion":[{"value":"26 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}